solid tumours

A scientific debate is under way over the role of a truncated ALK transcript in solid tumours. One view treats it as a promising biomarker for diagnosing or stratifying cancers, while sceptics question whether it has real biological function or is largely overhyped. The discussion reflects a wider push in oncology to validate novel transcript-based markers before they enter clinical practice.